+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Macular Degeneration Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 250 Pages
  • December 2023
  • Region: Global
  • Fairfield Market Research
  • ID: 5922702
Description Jump to:
The global macular degeneration treatment market, valued at approximately US$ 9.9 billion in 2024, is poised for substantial growth, with an estimated valuation of US$ 18 billion by 2031. Age-related macular degeneration (AMD), a leading cause of vision loss and blindness worldwide, is driving the demand for innovative treatment solutions.

The Global AMD Challenge:

AMD represents a significant global healthcare challenge, with estimates suggesting that the number of AMD sufferers could surge from 9.1 million in 2010 to 17.8 million by 2050. To address this growing concern, the development of effective and accessible treatments is essential, particularly in regions with limited access to costly anti-vascular endothelial growth factor (anti-VEGF) injection therapies.

Key Drivers of Market Expansion:

Rising Prevalence of Retinal Disorders: The increasing burden of retinal diseases, coupled with the growing elderly population, is a primary driver of the macular degeneration treatment market. For example, in Europe, AMD affects over 67 million people, and this number is expected to rise by 15% by 2050 due to population aging, fueling the demand for macular degeneration therapies.

Development of Long-Acting Anti-VEGF Drugs: Long-acting anti-VEGF drugs are creating lucrative opportunities for manufacturers. These drugs offer sustained drug delivery, overcoming the need for frequent and uncomfortable intraocular injections. Innovations like Beovu and Vabysmo are expected to drive market expansion in the coming years.

Challenges to Market Growth:

High Cost of Patented Drugs: Patent expirations pose a challenge to market participants. The cost-effectiveness of prescription medications will be a critical factor in maintaining market growth.

Country-wise Insights:

U.S. Market: The U.S. accounted for 91.8% of the North American macular degeneration treatment market in 2021. Favorable government initiatives, increased R&D partnerships, the presence of key industry players, and product launches are expected to drive significant market growth in the U.S.

U.K. Market: With over 1.5 million individuals suffering from macular disease, the U.K. presents a lucrative market due to the high prevalence of AMD, especially among people over the age of 55. AMD is the leading cause of blindness in the country, further highlighting the need for effective treatments.

China Market: China's vast population base, increasing treatment adoption rates, and rising disposable income have led to higher diagnosis and treatment rates. The prevalence of AMD-related blindness and vision loss has nearly doubled in the country in the last 30 years, making China a prominent market in East Asia.

Competitive Landscape:

Major players in the macular degeneration treatment market are actively pursuing research collaborations to develop novel products. Additionally, several companies have robust therapeutic pipelines with plans for patient protection and licensing.

Key Companies Profiled:

  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Bayer AG
  • Pfizer Inc.
  • Bausch Health Companies Inc.
  • Regeneron Pharmaceuticals Inc.
  • Amgen Inc.
  • Biogen
  • Samsung Bioepis
  • Santen Pharmaceutical Co., Ltd.

Macular Degeneration Treatment Industry Research Segmentation

By Drug:

  • Anti-vascular Endothelial Growth Factors
  • Others

By Indication:

  • Dry Age-related Macular Degeneration
  • Wet Age-related Macular Degeneration

By Route of Administration:

  • Intravenous Route
  • Intravitreal Route
  • Others

By Distribution Channel:

  • Hospitals
  • Ophthalmology Clinics
  • Ambulatory Surgical Centers
  • Others

By Region:

  • North America
  • Latin America
  • Europe Macular
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Macular Degeneration Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Macular Degeneration Treatment Market Outlook, 2018 - 2031
3.1. Global Macular Degeneration Treatment Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Anti-vascular Endothelial Growth Factors
3.1.1.2. Others
3.2. Global Macular Degeneration Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Dry Age-related Macular Degeneration
3.2.1.2. Wet Age-related Macular Degeneration
3.3. Global Macular Degeneration Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Intravenous Route
3.3.1.2. Intravitreal Route
3.3.1.3. Others
3.4. Global Macular Degeneration Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. Hospitals
3.4.1.2. Ophthalmology Clinics
3.4.1.3. Ambulatory Surgical Centers
3.4.1.4. Others
3.5. Global Macular Degeneration Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.5.1. Key Highlights
3.5.1.1. North America
3.5.1.2. Europe
3.5.1.3. Asia Pacific
3.5.1.4. Latin America
3.5.1.5. Middle East & Africa
4. North America Macular Degeneration Treatment Market Outlook, 2018 - 2031
4.1. North America Macular Degeneration Treatment Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Anti-vascular Endothelial Growth Factors
4.1.1.2. Others
4.2. North America Macular Degeneration Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Dry Age-related Macular Degeneration
4.2.1.2. Wet Age-related Macular Degeneration
4.3. North America Macular Degeneration Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Intravenous Route
4.3.1.2. Intravitreal Route
4.3.1.3. Others
4.4. North America Macular Degeneration Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. Hospitals
4.4.1.2. Ophthalmology Clinics
4.4.1.3. Ambulatory Surgical Centers
4.4.1.4. Others
4.5. North America Macular Degeneration Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.5.1. Key Highlights
4.5.1.1. U.S. Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
4.5.1.2. U.S. Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
4.5.1.3. U.S. Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
4.5.1.4. U.S. Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.5.1.5. Canada Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
4.5.1.6. Canada Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
4.5.1.7. Canada Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
4.5.1.8. Canada Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.5.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Macular Degeneration Treatment Market Outlook, 2018 - 2031
5.1. Europe Macular Degeneration Treatment Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Anti-vascular Endothelial Growth Factors
5.1.1.2. Others
5.2. Europe Macular Degeneration Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Dry Age-related Macular Degeneration
5.2.1.2. Wet Age-related Macular Degeneration
5.3. Europe Macular Degeneration Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Intravenous Route
5.3.1.2. Intravitreal Route
5.3.1.3. Others
5.4. Europe Macular Degeneration Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Hospitals
5.4.1.2. Ophthalmology Clinics
5.4.1.3. Ambulatory Surgical Centers
5.4.1.4. Others
5.5. Europe Macular Degeneration Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.5.1. Key Highlights
5.5.1.1. Germany Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
5.5.1.2. Germany Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
5.5.1.3. Germany Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.5.1.4. Germany Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.1.5. U.K. Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
5.5.1.6. U.K. Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
5.5.1.7. U.K. Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.5.1.8. U.K. Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.1.9. France Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
5.5.1.10. France Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
5.5.1.11. France Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.5.1.12. France Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.1.13. Italy Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
5.5.1.14. Italy Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
5.5.1.15. Italy Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.5.1.16. Italy Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.1.17. Turkey Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
5.5.1.18. Turkey Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
5.5.1.19. Turkey Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.5.1.20. Turkey Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.1.21. Russia Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
5.5.1.22. Russia Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
5.5.1.23. Russia Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.5.1.24. Russia Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.1.25. Rest of Europe Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
5.5.1.26. Rest of Europe Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
5.5.1.27. Rest of Europe Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.5.1.28. Rest of Europe Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Macular Degeneration Treatment Market Outlook, 2018 - 2031
6.1. Asia Pacific Macular Degeneration Treatment Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Anti-vascular Endothelial Growth Factors
6.1.1.2. Others
6.2. Asia Pacific Macular Degeneration Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Dry Age-related Macular Degeneration
6.2.1.2. Wet Age-related Macular Degeneration
6.3. Asia Pacific Macular Degeneration Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Intravenous Route
6.3.1.2. Intravitreal Route
6.3.1.3. Others
6.4. Asia Pacific Macular Degeneration Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. Hospitals
6.4.1.2. Ophthalmology Clinics
6.4.1.3. Ambulatory Surgical Centers
6.4.1.4. Others
6.5. Asia Pacific Macular Degeneration Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.5.1. Key Highlights
6.5.1.1. China Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
6.5.1.2. China Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
6.5.1.3. China Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.5.1.4. China Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.5.1.5. Japan Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
6.5.1.6. Japan Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
6.5.1.7. Japan Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.5.1.8. Japan Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.5.1.9. South Korea Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
6.5.1.10. South Korea Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
6.5.1.11. South Korea Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.5.1.12. South Korea Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.5.1.13. India Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
6.5.1.14. India Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
6.5.1.15. India Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.5.1.16. India Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.5.1.17. Southeast Asia Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
6.5.1.18. Southeast Asia Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
6.5.1.19. Southeast Asia Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.5.1.20. Southeast Asia Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.5.1.21. Rest of Asia Pacific Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
6.5.1.22. Rest of Asia Pacific Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
6.5.1.23. Rest of Asia Pacific Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.5.1.24. Rest of Asia Pacific Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Macular Degeneration Treatment Market Outlook, 2018 - 2031
7.1. Latin America Macular Degeneration Treatment Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Anti-vascular Endothelial Growth Factors
7.1.1.2. Others
7.2. Latin America Macular Degeneration Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Dry Age-related Macular Degeneration
7.2.1.2. Wet Age-related Macular Degeneration
7.3. Latin America Macular Degeneration Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Intravenous Route
7.3.1.2. Intravitreal Route
7.3.1.3. Others
7.4. Latin America Macular Degeneration Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Hospitals
7.4.1.2. Ophthalmology Clinics
7.4.1.3. Ambulatory Surgical Centers
7.4.1.4. Others
7.5. Latin America Macular Degeneration Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.5.1. Key Highlights
7.5.1.1. Brazil Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
7.5.1.2. Brazil Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
7.5.1.3. Brazil Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
7.5.1.4. Brazil Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.5.1.5. Mexico Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
7.5.1.6. Mexico Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
7.5.1.7. Mexico Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
7.5.1.8. Mexico Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.5.1.9. Argentina Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
7.5.1.10. Argentina Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
7.5.1.11. Argentina Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
7.5.1.12. Argentina Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.5.1.13. Rest of Latin America Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
7.5.1.14. Rest of Latin America Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
7.5.1.15. Rest of Latin America Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
7.5.1.16. Rest of Latin America Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Macular Degeneration Treatment Market Outlook, 2018 - 2031
8.1. Middle East & Africa Macular Degeneration Treatment Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Anti-vascular Endothelial Growth Factors
8.1.1.2. Others
8.2. Middle East & Africa Macular Degeneration Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Dry Age-related Macular Degeneration
8.2.1.2. Wet Age-related Macular Degeneration
8.3. Middle East & Africa Macular Degeneration Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Intravenous Route
8.3.1.2. Intravitreal Route
8.3.1.3. Others
8.4. Middle East & Africa Macular Degeneration Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. Hospitals
8.4.1.2. Ophthalmology Clinics
8.4.1.3. Ambulatory Surgical Centers
8.4.1.4. Others
8.5. Middle East & Africa Macular Degeneration Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.5.1. Key Highlights
8.5.1.1. GCC Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
8.5.1.2. GCC Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
8.5.1.3. GCC Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.5.1.4. GCC Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.5.1.5. South Africa Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
8.5.1.6. South Africa Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
8.5.1.7. South Africa Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.5.1.8. South Africa Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.5.1.9. Egypt Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
8.5.1.10. Egypt Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
8.5.1.11. Egypt Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.5.1.12. Egypt Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.5.1.13. Nigeria Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
8.5.1.14. Nigeria Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
8.5.1.15. Nigeria Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.5.1.16. Nigeria Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.5.1.17. Rest of Middle East & Africa Macular Degeneration Treatment Market by Drug, Value (US$ Bn), 2018 - 2031
8.5.1.18. Rest of Middle East & Africa Macular Degeneration Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
8.5.1.19. Rest of Middle East & Africa Macular Degeneration Treatment Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.5.1.20. Rest of Middle East & Africa Macular Degeneration Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Drug vs Indication Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. F. Hoffmann-La Roche Ltd.
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Novartis AG
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Bayer AG
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Pfizer Inc.
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Bausch Health Companies Inc.
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Zydus Cadila Healthcare Ltd.
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Regeneron Pharmaceuticals Inc.
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Amgen Inc.
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Biogen
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Samsung Bioepis
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
9.4.11. Santen Pharmaceutical Co., Ltd.
9.4.11.1. Company Overview
9.4.11.2. Product Portfolio
9.4.11.3. Financial Overview
9.4.11.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Bayer AG
  • Pfizer Inc.
  • Bausch Health Companies Inc.
  • Regeneron Pharmaceuticals Inc.
  • Amgen Inc.
  • Biogen
  • Samsung Bioepis
  • Santen Pharmaceutical Co., Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Macular Degeneration Treatment Market Report by Type, Stage of Disease, Route of Administration, End User, and Region 2024-2032 - Product Image

Macular Degeneration Treatment Market Report by Type, Stage of Disease, Route of Administration, End User, and Region 2024-2032

  • Report
  • 137 Pages
  • Global
From
Macular Degeneration Treatment Global Market Report 2024 - Product Image

Macular Degeneration Treatment Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Age-Related Macular Degeneration Global Market Report 2024 - Product Image

Age-Related Macular Degeneration Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Age-Related Macular Degeneration Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Age-Related Macular Degeneration Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 128 Pages
  • Global
From
Dry Age-related Macular Degeneration (Dry-AMD) - Pipeline Insight, 2024 - Product Image

Dry Age-related Macular Degeneration (Dry-AMD) - Pipeline Insight, 2024

  • Clinical Trials
  • 240 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.